14 Oct 2016
N+1 Singer - Oxford BioMedica - Forecasts updated, upgrade to Hold
We have updated our forecasts on Oxford BioMedica this morning following interim results and £10m (net) fundraising announced on 13 September 2016. Novartis remains on track to file a biologics license application (BLA) for CTL019 (Acute Lymphoblastic Leukaemia) in early 2017. Oxford BioMedica is confident that it will become supplier for the commercial launch of the product in H2 2017 as well as benefit from a royalty on the product. Following the substantial capex programme undertaken in the l ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Forecasts updated, upgrade to Hold
Oxford BioMedica plc (OXB:LON) | 201 7.7 1.9% | Mkt Cap: 201.3m
- Published:
14 Oct 2016 -
Author:
Sheena Berry -
Pages:
3
We have updated our forecasts on Oxford BioMedica this morning following interim results and £10m (net) fundraising announced on 13 September 2016. Novartis remains on track to file a biologics license application (BLA) for CTL019 (Acute Lymphoblastic Leukaemia) in early 2017. Oxford BioMedica is confident that it will become supplier for the commercial launch of the product in H2 2017 as well as benefit from a royalty on the product. Following the substantial capex programme undertaken in the l ....